Portal de Periódicos da CAPES

High-speed, Ultrahigh Resolution Optical Coherence Tomography of the Retina in Hunter Syndrome

2007; Volume: 38; Issue: 5 Linguagem: Inglês

10.3928/15428877-20070901-14

2325-8179

Michael K. Yoon, Royce W. S. Chen, Thomas R. Hedges, Vivek J. Srinivasan, Iwona Gorczyńska, James G. Fujimoto, Maciej Wojtkowski, Joel S. Schuman, Jay S. Duker,

Retinal and Macular Surgery

<P>A 42-year-old man with Hunter syndrome developed bilateral visual field loss. Visual field testing demonstrated bilateral ring scotomata that corresponded to areas of thinning seen on standard resolution optical coherence tomography. High-speed, ultrahigh resolution optical coherence tomography, capable of 3.5-micron axial resolution, showed a loss of photoreceptors outside the fovea and cystoid spaces within the inner nuclear, ganglion cell, and outer nuclear layers. These results were consistent with histopathologic features that have been reported previously in patients with Hunter syndrome. Optical coherence tomography could be used as a diagnostic modality to monitor patients with Hunter syndrome and to detect subclinical forms of disease. [<CITE>Ophthalmic Surg Lasers Imaging</CITE> 2007;38:423-428.]</P> <H4>AUTHORS</H4> <P>From New England Eye Center (MKY, RWC, TRH, IG, MW, JSD), Tufts-New England Medical Center, Tufts University, Boston, Massachusetts; the Department of Electrical Engineering and Computer Science and Research Laboratory of Electronics (VJS, IG, JGF, MW), Massachusetts Institute of Technology, Cambridge, Massachusetts; and UPMC Eye Center and the Eye and Ear Institute (JSS), Ophthalmology and Visual Science Research Center, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania</P> <P>Accepted for publication April 20, 2007.</P> <P>Supported in part by National Institutes of Health RO1-EY13178-06, RO1-EY11289-20, P30-EY08098, P30-EY13078, Air Force Office of Scientific Research, Medical Free Electron Laser Program contract FA9550-040- 1-0046, FA9550-040-1-0011, National Science Foundation ECS-0119452, BES-0522845, The Eye and Ear Foundation (Pittsburgh, PA), and Research to Prevent Blindness Unrestricted Grant and Medical Student Eye Research Fellowship.</P> <P>Drs. Fujimoto and Schuman receive royalties from intellectual property licensed by the Massachusetts Institute of Technology to Carl Zeiss Meditec, and Drs. Duker and Schuman receive research support from Optovue, Inc. Dr. Schuman also receives research support from Alcon Laboratories, Inc., Allergan, Inc., SOLX, and Clarity, and receives lecture fees from Alcon Laboratories, Inc., Allergan, Inc., Carl Zeiss Meditec, Merck U.S. Human Health, the National Eye Institute, Heidelberg Engineering, Inc., and Optovue, Inc.</P> <P>Dr. Schuman did not participate in the editorial review of this manuscript.</P> <P>Address correspondence to Thomas R. Hedges III, MD, Ophthalmology Department, Tufts-New England Medical Center, 750 Washington Street, Boston, MA 02111.</P>